Brief: Compugen Announces First Development Milestone In License Agreement With Astrazeneca For The Development Of Bispecific And Multi-Specific Antibody Products
23/12/2020 12:14
Dec 23 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN ANNOUNCES FIRST DEVELOPMENT MILESTONE IN LICENSE
AGREEMENT WITH ASTRAZENECA FOR THE DEVELOPMENT OF BISPECIFIC AND
MULTI-SPECIFIC ANTIBODY PRODUCTS
* COMPUGEN LTD - ANNOUNCED PROGRESS FROM ITS ONGOING
LICENSE
AGREEMENT WITH ASTRAZENECA UNDER WHICH PROGRAM HAS ACHIEVED A
PRECLINICAL MILESTONE
* COMPUGEN LTD - IN CONNECTION WITH THE FIRST MILESTONE,
COMPUGEN
IS ENTITLED TO RECEIVE A $2 MILLION PAYMENT FROM ASTRAZENECA
Source text for Eikon: ID:nPn3F42Lga
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025